

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/808,885	03/14/2001	Jennifer L. Hillman	PF-0354-2 DIV	5250
7	590 05/30/2002			
INCYTE GENOMICS, INC. PATENT DEPARTMENT 3160 Porter Drive			EXAMINER	
			HARRIS, ALANA M	
Palo Alto, CA 94304			ART UNIT	PAPER NUMBER
			1642	12
			DATE MAILED: 05/30/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/808,885	HILLMAN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Alana M. Harris, Ph.D.	1642			
The MAILING DATE of this communication appears on the cover sheet with the c rrespondence address Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status					
1) Responsive to communication(s) filed on					
_	is action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>					
4)⊠ Claim(s) <u>1-19</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6) ☐ Claim(s) is/are rejected.					
7)☐ Claim(s) is/are objected to.					
8)⊠ Claim(s) <u>1-19</u> are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No					
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) The translation of the foreign language provisional application has been received.  15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) D Notice of Informal I	v (PTO-413) Paper No(s) Patent Application (PTO-152) uation Sheet .			

Continuation of Attachment(s) 6). Other: Restriction Election Facsimile Transmission.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1 and 2, drawn to an isolated polypeptide, classified in class 530, subclass 350.
- Claims 3, 5, 6, 8, 11, 12 and 14-17, drawn to an antibody, classified in class 530, subclass 387.1.
  - III. Claims 4, 7, 9, 18 and 19, drawn to a diagnostic test and a method of diagnosing a condition or disease comprising administering an antibody, classified in class 436, subclass 536.
- IV. Claims 10 and 13, drawn to a method of preparing antibodies, classified in class 435, subclass 70.21.
- 2. Groups I and II are structurally and functionally different products which are made by different methods and have different uses. The examination of all groups would require different searches in the U.S. Patent Shoes and the scientific literature and would require the consideration of different patentability issues.

The methods of Groups II and IV differ in the method objectives, method steps and parameters and in the reagents used.

Inventions II and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different

Application/Control Number: 09/808,885

Art Unit: 1642

process of using that product (MPEP § 806.05(h)). In the instant case the product of Group II can be made either by the method of Group IV or by antibody phage display library technology.

Inventions II and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptide of Group II can be used in the diagnostic test of Group III or in an in vivo treatment method.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. A telephone call was made to David Streeter, Ph.D. on May 27, 2002 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Application/Control Number: 09/808,885

Art Unit: 1642

5. Applicant is reminded that upon the cancellation of claims to a non-elected

invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one

Page 4

or more of the currently named inventors is no longer an inventor of at least one claim

remaining in the application. Any amendment of inventorship must be accompanied by

a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

6. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is

(703) 306-5880. The examiner can normally be reached on 6:30 am to 4:00 pm, with

alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Anthony Caputa, Ph.D. can be reached on (703) 308-3995. The fax phone

numbers for the organization where this application or proceeding is assigned are (703)

308-4315 for regular communications and (703) 308-4315 for After Final

communications.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to the receptionist whose telephone number is (703)308-

0196.

Alana M. Harris, Ph.D.

May 30, 2002